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 2 
Abstract 35 
Hepatitis C virus (HCV) is a single-stranded positive-sense RNA hepatotropic 36 
virus. Despite cellular defenses, HCV is able to replicate in hepatocytes and 37 
to establish a chronic infection that could lead to severe complications and 38 
hepatocellular carcinoma.  An important player in subverting the host 39 
response to HCV infection is the viral non-structural protein NS5A that, in 40 
addition to its role in replication and assembly, targets several pathways 41 
involved in the cellular response to viral infection. Several unbiased screens 42 
identified the nucleosome-assembly protein 1-like 1 (NAP1L1) as an 43 
interaction partner of HCV NS5A. Here we confirm this interaction and map it 44 
to the C-terminus of NS5A of both genotype 1 and 2. NS5A sequesters 45 
NAP1L1 in the cytoplasm blocking its nuclear translocation. However, only 46 
NS5A from genotype 2 HCV, but not from genotype 1, targets NAP1L1 for 47 
proteosomal-mediated degradation. NAP1L1 is a nuclear chaperone involved 48 
in chromatin remodeling and we demonstrate the NAP1L1-dependent 49 
regulation of specific pathways involved in cellular responses to viral infection 50 
and cell survival. Among those we show that lack of NAP1L1 leads to a 51 
decrease of RELA protein levels and a strong defect of IRF3 TBK1/IKKε-52 
mediated phosphorylation leading to inefficient RIG-I and TLR3 responses. 53 
Hence, HCV is able to modulate the host cell environment by targeting 54 
NAP1L1 through NS5A.  55 56 
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Importance 57 
Viruses have evolved to replicate and to overcome antiviral countermeasures 58 
of the infected cell. The hepatitis C virus is capable of establishing a life-long 59 
chronic infection in the liver, which could develop into cirrhosis and cancer. 60 
Chronic viruses are particularly able to interfere with the cellular antiviral 61 
pathways by several different mechanisms. In this study we identify a novel 62 
cellular target of the viral non-structural protein NS5A and demonstrate its role 63 
in antiviral signaling. This factor, called nucleosome-assembly protein like 1 64 
(NAP1L1), is a nuclear chaperone involved in the remodeling of chromatin 65 
during transcription. When depleted, specific signaling pathways leading to 66 
antiviral effectors are affected. Therefore, we provide both evidence for a 67 
novel strategy of virus evasion from cellular immunity and a novel role for a 68 
cellular protein, which has not been described to date. 69 
 70 
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 4 
Introduction 74 
HCV is a member of the Flaviviridae family, genus Hepacivirus, with a 75 
single-stranded positive-polarity RNA genome of approximately 9.6 kb (1). 76 
Seven viral genotypes (1 to 7) have been identified with important differences 77 
in geographical distribution, pathogenesis and response to treatment (2). The 78 
HCV life cycle is entirely cytoplasmic and involves entry, uncoating and 79 
translation of the viral RNA to a polyprotein that is processed by proteolysis 80 
into 3 structural (Core, E1 and E2) and 7 non-structural proteins (p7, NS2, 81 
NS3, NS4A, NS4B, NS5A, NS5B). Viral RNA translation, replication and 82 
subsequent steps of particle assembly and release takes place associated 83 
with remodelled intracellular membranes and lipid droplets (LD) (3-5). Non-84 
structural proteins are required for RNA replication, with NS3-NS4A being the 85 
helicase/proteinase and NS5B being the viral RNA-dependent RNA 86 
polymerase. In addition, HCV non-structural proteins have also been 87 
implicated in perturbing cell signalling and mediating immune evasion. Among 88 
them, NS5A has been implicated in subverting several cellular pathways and 89 
as a candidate viral oncogene. 90 
NS5A is a 447aa (gt-2a) phosphoprotein that is found associated to ER 91 
membranes through an N-terminal amphipathic helix (aa 1-27). The rest of the 92 
polypeptide is hydrophilic and consists of a large amino-terminal domain I 93 
followed by two smaller, more variable domains II and III. Domains I and II are 94 
essential for viral genome replication while domain III is dispensable for 95 
genome replication, but is required for viral particle assembly via interaction 96 
with Core (6-8). A cluster of phosphorylated Serine residues at position 97 
452/454/457 (strain JFH1 gt-2a) at the very C-terminal end of NS5A is 98 
responsible for this interaction. In addition to a direct role in HCV genome 99 
replication and assembly, NS5A makes an important contribution to 100 
modulating the host cell environment. NS5A is a promiscuous protein and 101 
interacts with several host factors thus affecting different signalling pathways 102 
that control cell cycle, apoptosis and the interferon response to viral infection 103 
(reviewed in: (9, 10)). 104 
Chronic infection with HCV is a major risk factor for the development of 105 
hepatocellular carcinoma (HCC) (11). The leading hypothesis is that 106 
malignant transformation of hepatocytes occurs through increased liver cell 107 
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turnover induced by chronic liver injury and regeneration, in a context of 108 
inflammation and oxidative DNA damage. However, increasing experimental 109 
evidence suggests that HCV might also contribute to malignant transformation 110 
of hepatocytes through the direct action of viral proteins on cellular 111 
transformation pathways (12). Liver-specific expression in transgenic mice of 112 
the full viral polyprotein (Core to NS5B) at low levels, comparable to those 113 
found in patients, has been shown to induce HCC without inflammation (13). 114 
Mice transgenic for NS5A alone may also develop liver cancer, depending on 115 
the genetic background of the mice (14, 15). Furthermore, expression of 116 
NS5A in NIH3T3 fibroblasts promoted anchorage-independent growth and 117 
tumour formation in nude mice (16, 17). These data support a direct role of 118 
HCV proteins, and NS5A in particular, in the development of HCC. 119 
In a recent attempt to identify host factors that associate with a number 120 
of innate immune-modulating viral proteins, Pichlmair et al. screened novel 121 
proteins that interact with HCV NS5A (18). Careful inspection of the data led 122 
to the unexpected observation that NS5A interacted with the human 123 
nucleosome assembly protein-like 1 (NAP1L1 or hNAP1). The interaction of 124 
NS5A with NAP1L1, or with the highly homologous NAP1L4, was 125 
independently identified in at least another three independent reports (19-21). 126 
NAP1L1 was originally identified in HeLa cells as the human homolog 127 
of the yeast nucleosome assembly protein 1 (NAP-1) (22). NAP1L1 is a 128 
391aa polypeptide characterized by nuclear import/export sequences and 129 
histone and protein binding domains (23). NAP1L1 is a chaperone and 130 
nucleo-cytoplasmic shuttling factor that facilitates the delivery and 131 
incorporation of two histone H2A-H2B dimers to complete the nucleosome 132 
(reviewed in (24-26)). NAP1L1 has been involved in the regulation of 133 
transcription, cell-cycle progression, incorporation and exchange of histone 134 
variants and promotion of nucleosome sliding. In addition, NAP1L1 has been 135 
shown to interact with several host and viral factors including the coactivator 136 
p300 and E2 of papillomaviruses (27-29). NAP1L1 interacts with the human 137 
immunodeficiency virus type 1 (HIV-1) Tat transactivator and enhances HIV-1 138 
trans-activation (30, 31). NAP1L1 family proteins are localized in the 139 
cytoplasm, but inhibition of nuclear export results in their accumulation in the 140 
nuclei indicating a shuttling activity that has been implicated also in the 141 
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delivery of histones to the nucleus as part of their chaperoning activity. 142 
NAP1L1 has been involved in the process of nucleosome depletion during 143 
embryonic stem cell differentiation (32). Knockdown of NAP1L1 enhanced the 144 
differentiation of iPSC into functional cardiomyocytes (33). NAP1L1 145 
expression has also been shown to be elevated in several cancers (34-36).  146 
In this work we confirm the interaction of NS5A with NAP1L1 and its 147 
co-localization in the cytoplasm of cells replicating HCV. The interaction could 148 
be mapped to the carboxy-terminus of domain III of NS5A, which is shared 149 
among all HCV genotypes. However, only NS5A from genotype 2, but not 150 
from genotype 1, targets NAP1L1 for proteosomal-mediated degradation. 151 
RNAseq analysis of NAP1L1-depleted cells shows dis-regulation of a number 152 
of genes from pathways of innate immunity and cell survival. Among those, 153 
we show that depletion of NAP1L1 leads to the down-modulation of NF-κB 154 
and to a strong down-regulation of IRF3 phosphorylation mediated by the 155 
kinase TBK1/IKKε. Both the RIG-I and TLR3 pathways were affected by 156 
NAP1L1 depletion. We conclude that HCV is able to modulate the host cell 157 
environment by targeting NAP1L1 through NS5A. We believe this may 158 
represent a novel strategy deployed by HCV to evade from cellular antiviral 159 
responses and possibly to maintain a chronic infection thus contributing to the 160 
development of HCC. 161 
 162 
 163 
 164 165 
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Results 166 
 167 
HCV NS5A binds NAP1L1  168 
In independent reports, the non-structural protein 5A (NS5A) from the 169 
human hepatitis C virus (HCV) has been repeatedly found to interact with the 170 
nucleosome assembly protein NAP1L1 (18-21). However, such reports didn’t 171 
map the interaction or conducted additional functional studies. To confirm the 172 
interaction we generated a full-length flag-tagged f-NS5A (N-terminus) derived 173 
from JFH1 genotype 2a (gt2a). Co-transfection of f-NS5A with HA-NAP1L1 in 174 
HEK 293T cells followed by anti-flag affinity chromatography resulted in the 175 
detection of HA-NAP1L1 (Figure 1A). As a positive control for the interaction 176 
we used the human immunodeficiency virus Tat protein, which has been 177 
previously described to bind NAP1L1 (30, 31). To study the interaction of 178 
NS5A with NAP1L1 at the endogenous levels we took advantage of the JFH1 179 
subgenomic replicon (SGR-JFH1/Luc), which efficiently replicates in 180 
hepatocytes. As shown in Figure 1B, the interaction was preserved, albeit with 181 
a very low efficiency of immunoprecipitation, which could be explained by an 182 
effect of NS5A on the stability of the protein (see below). Furthermore, 183 
extensive colocalization of the two proteins was observed in the cytoplasm 184 
(Figure 1C). Interestingly, the extent of the co-localization increased from 185 
approximately 10% of NS5A expressing cells at 48 hpe to more than 70% at 186 
72 hpe (not shown). We repeated the experiment with a sub-genomic replicon 187 
that expresses also HCV Core (Luc-JFH1ΔE1/E2) (37). In this case NS5A 188 
drives the localization of NAP1L1 to subcellular locations reminiscent of lipid 189 
droplets (Figure 1C, lower panels). However, the interaction between NS5A 190 
and Core was not required for the NS5A to bind NAP1L1, as demonstrated in 191 
the experiments conducted in the absence of Core (Figure 1C top panels and 192 
Figure 1AB). 193 
 194 
HCV NS5A from gt2 mediates NAP1L1 proteosomal degradation 195 
 In order to investigate if the interaction with NAP1L1 was shared by 196 
NS5A from other HCV genotypes we performed an IP with genotype 1 (gt1) 197 
Con1- and H77-derived proteins. Surprisingly, NS5A from gt1 isolates was 198 
able to IP higher levels of NAP1L1 compared to JFH1 NS5A (Figure 2A). 199 
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Furthermore, co-transfection of HA-NAP1L1 with increasing amounts of JFH1 200 
NS5A (gt2) resulted in a decrease of NAP1L1 levels, while Con1 NS5A (gt1) 201 
did not  (Figure 2B). Hence, NS5A from JFH1 (gt2), but not those from Con1 202 
or H77 (gt1), resulted in the degradation of NAP1L1. Treatment with the 203 
inhibitor MG132 partially rescued the JFH1 NS5A degradation of NAP1L1 204 
indicating proteasome involvement (Figure 2C). Finally, cycloheximide 205 
treatment of SGR-JFH1/Luc transfected cells showed a progressive decrease 206 
of endogenous NAP1L1, although less efficiently than transfecting NS5A 207 
alone (Figure 2B), possibly related to the different levels of NS5A expression 208 
in the two experimental conditions.  Degradation of NS5A could be rescued by 209 
MG132, further highlighting the targeting of NAP1L1 for proteosomal-210 
mediated degradation also at physiological levels during HCV replication 211 
(Figure 2D). The major difference between JFH1-derived NS5A and those of 212 
the other HCV genotypes resides in a 20 amino acids insertion at the carboxy-213 
terminal end of the protein (Figure 2E), which also accounts for the 214 
differences of molecular weight observed (Figure 2A). 215 
We conclude that NAP1L1 binding is shared among NS5A derived from 216 
g1 and gt2 genotypes, but gt2 NS5A has the additional feature of being able 217 
to target NAP1L1 for proteosomal-mediated degradation. 218 
 219 
The carboxy-terminus of NS5A is required for NAP1L1 binding 220 
In order to map the interaction, NS5A from JFH1 was divided in three 221 
domains: Domain I (D1, nt. 2003-2189), Domain II (D2, nt. 2226-2314), 222 
Domain III (D3, nt. 2328-2442) all linked in various combinations to the N-223 
terminal amphipatic helix for membrane tethering, and flag-tagged at the N-224 
terminus (Figure 3A). As shown in Figure 3B, only constructs maintaining D3 225 
could interact with NAP1L1. Therefore, NS5A was further truncated from the 226 
C-terminus to generate proteins with progressive deletions. With this 227 
approach we found that deletions starting from the acidic motif 458-EEDD-461 228 
(AH-D3.5 in Figure 3C) completely abolished the interaction with NAP1L1. 229 
Since the acidic motif is a perfect consensus for casein kinase 2 mediated 230 
Serine phosphorylation (CK2: S-D/E-X-E/D) we reasoned that NAP1L1 231 
interacts with the C-terminal cluster of Serines already implicated in the 232 
interaction with HCV Core (6-8). To this end, we tested both the delB deletion 233 
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mutant of aa 2419-2433 (residues are numbered according to the positions 234 
within the original JFH1 polyprotein corresponding to aa 443-457 of NS5A) (7)  235 
and the triple mutant of cluster 3B (CL3B/SA or m2) (corresponding to 236 
S2428/2430/2433A, aa S452/454/457A of NS5A) (6). Co-IP analysis showed 237 
loss of interaction for both mutants (Figure 3D) further suggesting that these 238 
residues are crucial for NAP1L1 interaction. To further demonstrate that the 239 
co-localization requires the interaction of NS5A with NAP1L1 through the C-240 
terminal Serine-rich region we exploited two sub-genomic constructs SGR-241 
delB, and SGR-m2 (6, 7). NS5A from both constructs localized in clusters in 242 
the cytoplasm, like the wild-type replicon, but did not co-localize with NAP1L1, 243 
which remained diffused in the cytoplasm (Figure 3E). We conclude that 244 
NAP1L1 binds to the same cluster of serine residues at the carboxy-terminus 245 
of NS5A as the HCV core protein. 246 
 247 
NAP1L1 is not required for HCV replication and infectivity in Huh7 cells 248 
In order to assess the potential role of NAP1L1 in HCV replication we 249 
overexpressed the EYFP-tagged version of NAP1L1 in Huh7-Lunet cells by 250 
lentiviral vector (LV) transduction. NAP1L1-EYFP had the expected 251 
cytoplasmic localization and co-localized with NS5A when cells were 252 
transfected with SGR-JFH1 RNA (Figure 4A). However, there was no 253 
difference between cells overexpressing NAP1L1-EYFP or EYFP alone in the 254 
levels of luciferase from SGR-JFH/Luc, which is a measure of HCV genome 255 
replication (Figure 4B). Next, we efficiently depleted NAP1L1 by lentivectors 256 
delivering a specific shRNA (Figure 4C). Again, Huh7-Lunet cells replicated 257 
SGR-JFH/Luc in conditions of NAP1L1 depletion as well as in mock 258 
conditions (Figure 4D). To further confirm these results, we introduced full-259 
length genomic HCV JFH1 RNA into Huh7-lunet cells, which had been treated 260 
with shRNA as above. Cell culture supernatants at the indicated time points 261 
were used to infect naïve Huh7.5 cells to measure infectivity. As shown in 262 
Figure 4E, also HCV infectivity was not affected by NAP1L1 depletion in 263 
Huh7-lunet cells. Finally, we investigated the replication of HCV SGR-JFH/luc 264 
carrying the m2 mutation of NS5A. As shown in Figure 4F, wild type and m2 265 
replicons replicated equally well in Huh7-Lunet cells, compared to the non-266 
replicative control mutated in the polymerase NS5B GND. 267 
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We took the inverse approach to investigate the effect of NS5A on 268 
NAP1L1 activity. In physiological conditions in cell culture NAP1L1 is found 269 
predominantly in the cytoplasm (Figure 1C). However, incubation of cells with 270 
the nuclear export inhibitor Leptomycin B (LMB) results in the accumulation of 271 
NAP1L1 in the nucleus (Figure 5A) (31). Therefore, we transfected cells with 272 
SGR-JFH1 and its mutant m2 and monitored the localization of endogenous 273 
NAP1L1 in the nucleus. As shown in Figure 5A & 5B, SGR-driven NS5A, but 274 
not the m2 mutant, significantly inhibited nuclear localization of NAP1L1. To 275 
further analyze this phenotype in the context of HCV gt1 we engineered the 276 
corresponding m2 mutations also in Con1-derived NS5A (see Figure 2E for 277 
an alignment of the carboxyterminus of NS5A from the different genotypes). 278 
As shown in Figure 5C, Con1-derived NS5A m2 lost the ability to interact with 279 
NAP1L1 as expected. Interestingly, both JFH1 and Con1-derived NS5A 280 
equally inhibited nuclear translocation of NAP1L1 (Figure 5D & 5E).  281 
We conclude that NAP1L1 is not directly involved in HCV replication 282 
and infectivity, but NS5A from both genotypes affect NAP1L1 nuclear 283 
localization, possibly by sequestering NAP1L1 in the cytoplasm. Hence, we 284 
set to investigate the nuclear activity of NAP1L1.  285 
 286 
Transcriptome analysis of NAP1L1-depleted cells 287 
NAP1L1 is a nucleosome chaperone involved in several nuclear processes 288 
including transcription. Genome-wide analysis of yNAP1-deleted 289 
Saccharomyces cerevisiae showed that about 10% of all yeast open reading 290 
frames changed the transcription levels more than 2-fold (38). To investigate 291 
the transcriptome of hepatocytes we depleted NAP1L1 with shNAP1L1 292 
(Figure 4C). Differential analysis of the shNAP1L1 trascriptome versus cells 293 
transduced with the control shRNA (shCTRL) showed significant up-regulation 294 
of 144 genes (fold change ≥ 2) and down-regulation of 358 genes (fold 295 
change ≤ 2) with a false discovery rate of less than 0.05 (data derived from 296 
the most stringent DESEQ2 statistical analysis of Supplementary Table 1, 297 
which also shows the EDGR statistical analysis of the same data for 298 
comparison). These numbers correspond to approximately 1% of the total 299 
reads of the analysis (46623 reads) suggesting a good degree of specificity 300 
for the genes regulated by NAP1L1. To validate the sequencing data we re-301 
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tested a number of modulated genes by RT PCR as shown in Figure 6A. 302 
Ingenuity pathway analysis of down-regulated genes indicated that top 303 
canonical pathways involved in cancer and signaling were mostly affected 304 
(Supplementary Table 1). Interestingly, we also noticed down-modulation of 305 
interferon-stimulated genes (ISG) such as IFITM3, GBP2 and UBD as well as 306 
genes involved in interferon (IFN) transcriptional activation such as RELA 307 
(p65 subunit of NF-κB), c-Jun and GEF2 (39, 40). To investigate if the 308 
expression of the NAP1L1 target genes is reduced in HCV infected cells we 309 
conducted a meta-analysis of published data obtained in a similar setting (41). 310 
We found an overlap of 40 genes between the two analysis with 5 up-311 
regulated genes, 27 down-regulated genes and 8 genes showing opposed 312 
regulation. Interestingly, among the overlapping down-regulated genes we 313 
found again genes implicated in innate immunity regulation such as RELB, c-314 
Jun, and GEF2 (Supplementary Table 2). We also compared Huh7 cells 315 
stably replicating SGR JFH-1 with the homologous cured cells for the 316 
expression of some NAP1L1 regulated genes (not shown). We found that two 317 
significantly down-regulated genes in the context of NAP1L1 depletion such 318 
as GEF2 and IFTM1 where also down-regulated in conditions that favor HCV 319 
replication. However, other genes were not affected (CFL2 and HEPACAM2) 320 
or showed opposite regulation (UBD).  321 
In order to explore the impact of NAP1L1 depletion on the interferon 322 
response pathway we explored IFNα-mediated induction of IFITM3, GBP2 323 
and UBD (as well as IFIT1, IFIT3, OASL, IL8 and CXCL11, not shown). We 324 
found that these genes were not impaired in their IFN-dependent induction by 325 
NAP1L1 depletion, ruling out a specific role for NAP1L1 in ISG transcriptional 326 
activation (Figure 6B). Finally, in order to assess the effect of NAP1L1 327 
depletion on the induction of IFNβ we needed a different cell line from Huh7-328 
derived cells. To this end we used U2OS cells that maintain an intact IFN-329 
signaling pathway following poly(I:C) transfection, compared to cells more 330 
permissive to HCV such as Huh7-Lunet or Huh7.5 (Figure 6C) (42, 43). 331 
However, as shown in Figure 5D and 5E, the IFNβ response to poly(I:C) 332 
transfection in U2OS cells was completely obliterated in the absence of 333 
NAP1L1, both at the mRNA and protein level. Similar results were also 334 
obtained in the context of vesicular stomatitis virus infection (not shown). 335 
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These data indicate that NAP1L1 is involved in regulating pathways that lead 336 
to interferon induction. 337 
 338 
Involvement of NAP1L1 in the induction of IFN 339 
Pattern recognition receptors (PRR) like RIG-I/MDA5 and TLR3 respond to 340 
viral RNA agonists as well as to poly(I:C) by activating transcription factors 341 
such as NF-κB and IRF3. We observed previously that the NF-κB subunit 342 
RELA mRNA levels were reduced in the context of NAP1L1 depletion (Figure 343 
6A) and we confirmed this also at the protein level (Figure 7A and 344 
quantification Figure 7B). Following activation, RELA translocates into the 345 
nucleus as a phosphorylated protein. As shown in Figure 7A (quantification in 346 
Figure 7C), phosphorylation of RELA occurs 1-4 hours post polyI:C induction. 347 
In conditions of NAP1L1 depletion, albeit in conditions of reduced RELA 348 
protein content, phosphorylation occurs normally up to 4 hours post-349 
treatment, when a slight decrease was consistently observed (Figure 7A and 350 
quantification in Figure 7C). Nuclear translocation of RELA showed a 351 
significant decrease in the context of NAP1L1 depletion following polyI:C 352 
induction (Figure 7D and 7E). At variance with RELA, IRF3 protein levels 353 
were not changed by NAP1L1 depletion (Figure 7A). However, IRF3 354 
phosphorylation was profoundly affected (Figure 7A and quantification in 355 
Figure 7C) as well as IRF3 nuclear translocation (Figure 7F and 7G). Finally 356 
we wished to recapitulate the phenotype of NAP1L1 depletion using HCV 357 
NS5A. Wild-type NS5A inhibits TBK1-mediated activation of the IFN response 358 
(Figure 7H), but the activity was rescued by the NS5A mutant that cannot bind 359 
NAP1L1. These results suggest that NAP1L1 depletion regulates the innate 360 
immune response by down-modulating RELA protein levels and by inhibiting 361 
IRF3 phosphorylation. 362 
 363 
Molecular basis of NAP1L1 depletion on IRF3 phosphorylation 364 
IRF3 phosphorylation is the consequence of a complex series of molecular 365 
events (see diagram in Figure 8A). PRRs such as RIG-I recognize the RNA 366 
agonist in the cytoplasm and bind the adaptor protein IPS-1/MAVS to trigger 367 
the downstream kinases TBK1/IKKε, which then phosphorylate IRF3. TLR3 368 
instead recognizes the RNA agonist within endosomes and signals through 369 
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the adaptor TRIF to induce IRF3 phosphorylation. Since NAP1L1 depletion 370 
could affect each of these steps, we proceeded to dissect the whole signaling 371 
pathway. First, we took advantage of the constitutively active phosphomimetic 372 
IRF3-5D (44). Consistent with our interpretation, induction of IFNβ by IRF3-5D 373 
was not affected by NAP1L1 depletion (Figures 8B & 8C). Conversely, 374 
depletion of NAP1L1 resulted in the inhibition of each step of the RIG-I 375 
pathway, from MAVS down to TBK1/IKKε kinases. With a similar approach, 376 
we could demonstrate that the TLR3 adaptor protein TRIF activity is inhibited 377 
by NAP1L1 depletion (Figure 9A). To further investigate this pathway we 378 
reconstituted the TLR3 pathway in Huh7-lunet cells depleted for NAP1L1 379 
(Figures 9B & 9C). Stimulation with exogenous p(I:C) induced high levels of 380 
the ISG IFIT1 (interferon induced protein with tetratricopeptide repeats 1), 381 
which was severely affected by NAP1L1 depletion (Figure 9D). We conclude 382 
that NAP1L1 controls both arms of innate sensing at the IRF3 crossroad.  383 
 384 
 385 386 
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Discussion 387 
 388 
The co-evolution of viruses with their host results in a number of defense 389 
strategies and countermeasures. Particularly for chronic infections, where the 390 
virus persists for long periods of time, a delicate equilibrium is established to 391 
permit limited virus replication in the context of a permissive cellular 392 
environment. HCV is highly successful at establishing a chronic infection, with 393 
about 80% of patients that become chronically infected. In this work we 394 
describe several lines of evidence that identify NAP1L1 as a key cellular 395 
effector of innate sensing and propose a novel mechanism that the virus 396 
deploys to subvert innate immunity in infected hepatocytes. 397 
First, we confirmed that NAP1L1 is a bona fide interactor of NS5A. These 398 
data are in support of a series of independent observations from other groups 399 
that indicated NAP1L1 and/or NAP1L4 as binding partners for NS5A, but 400 
failed to identify a functional role (18-21). We mapped the interaction at the 401 
extreme carboxy-terminus of NS5A, in a conserved motif encompassing three 402 
Serine residues that have been implicated in the interaction of NS5A with 403 
Core, which is essential for virus assembly, but dispensable for HCV genome 404 
replication (Figure 4F) (6-8). Interestingly, NAP1L1 has also been identified as 405 
a binding partner of Core in the same proteomic screenings that identified it 406 
as a binding partner of NS5A (18, 21). Indeed, in the presence of Core, we 407 
could visualize NAP1L1 on the surface of lipid droplets together with NS5A 408 
and Core. However, interaction with Core appears not to be essential for 409 
NAP1L1 and NS5A interaction, since experiments conducted in the absence 410 
of Core showed efficient interaction and co-localization. Therefore, Core and 411 
NAP1L1 bind independently the same region of NS5A. Unfortunately, 412 
mutagenesis of the binding motif in NS5A results in the disruption of both 413 
Core and NAP1L1 interactions and in a defect in assembly for viruses 414 
generated with these mutations, thus precluding their use unless these two 415 
interactions are uncoupled, if at all possible. 416 
Next we questioned the functional role of the interaction. We discovered that 417 
NS5A from genotype 2 was able to bind and degrade NAP1L1 through a 418 
proteosomal-dependent mechanism. NS5A from genotype 1 was also able to 419 
bind efficiently, but unable to degrade NAP1L1. Furthermore, wild-type NS5A 420 
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from both genotypes, but not the mutated version defective for NAP1L1 421 
binding, inhibited the nuclear re-localization of NAP1L1. It is well established 422 
that acutely infected patients respond well to IFN therapy while in chronically 423 
infected ones the response to IFN is variable and depends on the viral 424 
genotype (39, 45). Patients infected with HCV genotype 2 and 3 show a better 425 
response compared to genotypes 1 and 4, which correlates with higher levels 426 
hepatic ISG expression in HCV genotype 1 and 4 infected patient liver before 427 
therapy (46-49). The ability of different genotypes to subvert the innate 428 
response has been ascribed to the genetic variability of NS3 and NS5A, which 429 
could affect their known activities in targeting innate immunity effectors such 430 
as MAVS (NS3) or PKR and possibly NAP1L1 (NS5A). For example, the 431 
levels of MAVS cleavage in vivo showed a positive correlation with the 432 
decrease of the interferon response (50). In that report, HCV genotypes 2 and 433 
3 were more efficient than genotype 1 and 4 in MAVS cleavage and blockage 434 
of the endogenous IFN system, which determines the response to the 435 
treatment with pegylated IFN and ribavirin. Therefore we could speculate that 436 
also the differential ability of NS5A from genotype 1 (binding of NAP1L1) and 437 
2 (binding and degradation of NAP1L1) contributes to the observed responses 438 
following IFN treatment. However, the interaction of NS5A and NAP1L1 439 
appears functionally dominant over JFH1 dependent degradation. In fact, 440 
NS5A from the two genotypes were observed to be equally efficient in 441 
blocking NAP1L1 translocation into the nucleus (Figure 5C and D). 442 
Depletion of NAP1L1 by shRNA, which recapitulates NS5A-mediated 443 
inhibition, resulted in the modulation of several genes at the transcription 444 
level. In particular, we noticed down-modulation of interferon-stimulated genes 445 
(ISG), such as GBP2, IFITM3 and UBD, and genes involved in the 446 
transcriptional activation of IFNβ such as RELA, the p65 subunit of NFκB. 447 
Indeed, depletion of NAP1L1 strongly affected polyI:C mediated induction of 448 
IFNβ, while no effect was observed for IFNβ induction of ISGs. These findings 449 
restrict the functional role of NAP1L1 on HCV to the modulation of the innate 450 
sensing of the virus in infected cells. It is worthwhile noting that the latter 451 
experiments were conducted in U2OS cells, which are competent for the 452 
interferon response (43). Huh7-derived cell lines adapted for HCV growth are 453 
instead defective for the sensing of HCV replication (see Figure 5C) (42, 43). 454 
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Hence, NS5A control of NAP1L1 results in the inhibition of the cellular innate 455 
response pathway leading to IFNβ transcription, which is appreciable only in 456 
cells that maintain this pathway active. This observation clearly explains why 457 
we failed to observe any effect of NAP1L1 overexpression or depletion on 458 
HCV replication and infectivity in Huh7 derived cells.  459 
HCV infection triggers a number of innate immune pathways (39). The 5’-ppp 460 
and the poly U/UC sequence of viral RNA are potent activators of RIG-I 461 
signaling through MAVS/IPS-1 leading to the activation of the transcription 462 
factors IRF3 and NF-κB, which in turn drive transcription of IFNβ. HCV 463 
infection is also monitored in the host by the Toll-like receptors (TLRs). Viral 464 
RNA activates TLR3 and signals are transduced through the TIR-domain 465 
containing adapter-inducing IFNβ (TRIF) leading to activation of the 466 
transcription factors IRF3 and NFκB for the induction of innate immunity (51, 467 
52). Another recently described sensor protein for HCV is the antiviral protein 468 
kinase R (PKR). Kinase-independent PKR signaling activates specific ISGs 469 
and IFNβ early during HCV infection (53). This signaling induces protein–470 
protein interactions between PKR and MAVS, which have been previously 471 
described as a signaling adaptor protein also for PKR (54-56). Interestingly, 472 
all these pathways converge on the activation of transcription factors NFκB 473 
and/or IRF3. We found that depletion of NAP1L1 not only results in a 474 
significant reduction of the mRNA and protein levels of NFκB, but also 475 
severely impairs IRF3 phosphorylation. Furthermore, nuclear translocation of 476 
both NFκB and IRF3 following polyI:C stimulation of RIG-I is reduced when 477 
NAP1L1 is depleted. Therefore, NAP1L1 affects a step leading to IRF3 478 
phosphorylation, a conclusion that is further substantiated by an experiment 479 
where IFNβ expression induced by a constitutively active phosphorylated form 480 
of IRF3 (IRF3-5D) remains unaffected by NAP1L1 depletion, which rules out 481 
inhibitory effects downstream of IRF3 phosphorylation. In order to understand 482 
at which step NAP1L1 depletion was inhibiting the pathway upstream of IRF3 483 
we proceeded to dissect the major RIG-I dependent axis leading to IFNβ 484 
expression. We could consistently observe that depletion of NAP1L1 reduces 485 
INFβ expression induced by activated RIG-I, MAVS, TBK1 and IKKε. Hence, 486 
we can hypothesize that NAP1L1 depletion affects the RIG-I pathway at the 487 
level of TBK1/IKKε phosphorylation of IRF3. As mentioned above, at this step 488 
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converge all three pathways of IFNβ activation by HCV: RIG-I, TLR3 and 489 
PKR. Indeed, the TLR3 pathway was also inhibited by NAP1L1 depletion. 490 
Finally, to demonstrate that NS5A targeting of NAP1L1 is sufficient to inhibit 491 
this phosphorylation step we show that wild type NS5A, but not NS5A mutants 492 
defective for NAP1L1 binding, are able to inhibit IFNβ induction by TBK1. 493 
The master viral regulator of the HCV immune evasion program is the HCV 494 
NS3/4A protease. To regulate innate immune signaling, NS3/4A utilizes its 495 
protease domain to cleave key innate immune signaling adaptor proteins such 496 
as MAVS (57-60) and TRIF (61, 62). However, hepatitis A virus, a 497 
hepatotropic virus, which does not usually become chronic, encodes a 498 
protease that also cleaves MAVS (63). Thus, MAVS/TRIF cleavage is 499 
probably necessary but not sufficient for viral chronicity. HCV also regulates 500 
PKR activity during viral infection. HCV has several PKR-inactivation 501 
strategies that probably contribute to viral persistence in addition to NS3-502 
NS4A cleavage of MAVS, which depend on the activity of NS5A and E2 (64-503 
66). In this work we add another mechanism that could be deployed by HCV 504 
to subvert the host response to infection. We could not fully recapitulate the 505 
functional role of NAP1L1 in the infectious HCV life cycle due to a number of 506 
limitations of our experimental tools. First, mutations in NS5A that abolish 507 
NAP1L1 binding are not compatible with a fully infectious virus (6-8). Second, 508 
Huh7-derived cells that support HCV replication are impaired in the interferon 509 
response (Figure 6C). Third, Infection with full-length HCV would lead to 510 
several additional mechanisms of inhibition of the interferon response in 511 
addition to the NS5A/NAP1L1 axis, such as NS3/4A targeting MAVS and 512 
TRIF or NS2 inhibiting TBK/IKKε (39, 67). However, notwithstanding the 513 
limitations outlined above, we could clearly identify NAP1L1 as a target for 514 
HCV NS5A and define its novel role in the innate response. To note, a very 515 
recent report confirmed the interaction of HCV NS5A with NAP1L1 and 516 
showed some effect of NAP1L1 depletion on viral replication in the context of 517 
cells stably harboring a SGR HCV (68). It is possible that chronically 518 
replicating HCV is somehow more sensitive to NAP1L1 depletion. 519 
NAP1L1 is a cytoplasmic protein unless stimulated to translocate into the 520 
nucleus. Therefore we initially hypothesized a direct participation of NAP1L1 521 
in the TBK1/IKKε kinase complex that phosphorylates IRF3. However, we 522 
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failed to immunoprecipitate NAP1L1 together with TBK1 and IKKε (not 523 
shown). Most probably, the activity of NAP1L1 is at the transcriptional level 524 
instead, as we observed for the down-modulation of NFκB. NAP1L1 depletion 525 
and/or sequestration in the cytoplasm would result in the decrease of an as 526 
yet unknown cellular factor that promotes TBK1/IKKε phosphorylation of IRF3. 527 
Targeting general transcription factors to subvert innate sensing is not 528 
unusual. Several examples of viral proteins that target host cell transcription 529 
have been described. NSs from La Crosse encephalitis virus acts 530 
downstream of IRF3 by specifically inhibiting RNA polymerase II (RNAPII) 531 
mediated transcription by proteasomal degradation of the RBP1 subunit (69). 532 
Other Bunyaviruses interfere with RNAPII CTD Ser2 phosphorylation or target 533 
TFIIH (70-72). The NS1 of influenza A H3N2 subtype mimics a histone tail 534 
and suppresses hPAF1C-mediated transcriptional elongation of a subset of 535 
inducible genes involved in the antiviral response (73). Therefore, targeting 536 
transcription appears a generalized strategy to fine-tune transcriptional 537 
programs triggered by infection, which puts the cell in the optimal state to 538 
overcome the invaders’ attack. HCV makes no exception and we demonstrate 539 
here that by targeting NAP1L1, it is able to control a subset of host genes, 540 
including key components of the antiviral innate sensing. It will be important to 541 
investigate at the transcriptional level the mechanism of action of NAP1L1 and 542 
to identify the factor(s) involved in TBK1/IKKε IRF3 phosphorylation that are 543 
down-modulated when NAP1L1 is depleted. 544 
 545 546 
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Materials and Methods 547 
 548 
Cells and viruses 549 
The human hepatocarcinoma Huh7 cell line, its derivative Huh7-lunet kindly 550 
provided by Ralf Bartenschlager (University of Heidelberg, Germany) (74), the 551 
HEK293T cell line and the osteosarcoma cell line U2OS were cultured in 552 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 553 
bovine serum (FBS) and antibiotics. Cell cultures were maintained at 37 °C 554 
under 5% CO2. Cells were routinely tested for mycoplasma contamination. 555 
In vitro transcribed JFH1 RNA was introduced into Huh7-lunet cells by 556 
electroporation as described (75). The supernatants from cells electroporated 557 
with JFH1 RNA were removed at required time points and used to infect 558 
monolayers of naive Huh7.5 cells. Infected cells were detected at three days 559 
post-inoculation by indirect immunofluorescence using a polyclonal NS5A 560 
antiserum. The tissue culture 50% infectious dose (TCID50) was determined 561 
by limiting dilution assay (76). 562 
IFNα was obtained from the Biotechnology Development Group of the ICGEB. 563 
 564 
Plasmids 565 
Plasmid pJFH1 was provided by T. Wakita (77). Plasmids encoding SGR-566 
JFH1/Luc and the non-replicating control SGR-JFH1/Luc-GND were 567 
described previously (78). Plasmid pFKLuc-JFH/ΔE1-E2 was provided by R. 568 
Bartenschlager (37), plasmid SGR-JFH/m2 was provided by T. Masaki (6) 569 
and plasmid SGR-JFH1/delB by T. Tellinghuisen (7). The pHA-NAP1L1 and 570 
pNAP1L1-EYFP expression vectors were described previously (30, 31). 571 
pFLAG CMV-2 (Sigma-Aldrich) was used as backbone for all NS5A 572 
constructs. Flag tagged NS5A from HCV JFH1, Con1 and H77 were cloned 573 
by PCR of the corresponding HCV genotypes. Mutagenesis of NS5A (JFH1 574 
and Con1) was performed by PCR, detailed information is available on 575 
request. The reporter plasmid carrying the firefly luciferase (Fluc) gene under 576 
the control of the IFNβ  promoter (pIFNβ-Luc) was provided by J. Jung (44). T. 577 
Fujita kindly provided FLAG-tagged expression vectors for RIG-I, RIG-I-N, 578 
TBK1, IKKε, IPS-1/MAVS and HA-IRF3-5D. The control pCMV-Renilla was 579 
from Promega. 580 
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 581 
Lentivector production and shRNA delivery 582 
Overexpression of NAP1-EYFP and control EYFP was obtained by lentivector 583 
transduction on a pWPI backbone with blasticidin resistance (BLR) kindly 584 
provided by D. Trono. Lentiviral silencing vectors were derived from pLKO.1 585 
TRC (Addgene). The control short-hairpin RNA (shRNA) was the pLKO.1 586 
scramble from Addgene while for NAP1L1 targeting a specific targeting 587 
sequence was designed and cloned into pLKO.1 TRC (shNAP1L1) using the 588 
following oligonucleotides: 589 
5’-ccggcctattctgaagcacttgaaactgcagtttcaagtgcttcagaataggtttttg -3’ and 590 
5’- ggataagacttcgtgaactttgacgtcaaagttcacgaagtcttatccaaaaacttaa -3’. 591 
A LV for TLR3 reconstitution together with its GFP control was obtained from 592 
Sam Wilson (MRC – University of Glasgow Centre for Virus Research). 593 
Packaging in HEK 293T was performed according to standard procedures 594 
using the packaging plasmid psPAX2 and pMD2.G (Addgene). Cells’ 595 
supernatants were filtered and kept at -80 °C in small aliquots until use.  596 
 597 
In vitro transcription and electroporation of HCV SGR RNA 598 
The HCV SGR constructs were linearized with XbaI and treated with mung-599 
bean nuclease as described previously (79). RNA was transcribed in vitro 600 
from linearized constructs using the MEGAscript T7 kit (Ambion). Synthesized 601 
RNA was treated with DNase I and transfected into cells by  electroporation.  602 
PolyI:C (polyinosinic : polycytidylic acid sodium salt; Invivogen) was also 603 
transfected into cells by lipofection (Lipofectamine PLUS, Life Technologies) 604 
according to manufacturer’s instructons. 605 
 606 
Western-blotting, immunoprecipitation and immunofluorescence 607 
Indirect immunofluorescence analysis (IF) and Western-blotting (WB) were 608 
performed essentially as previously described (80). Immunoprecipitation (IP) 609 
was performed by lysis of cells in RIPA buffer (50 mM Tris HCl pH7.5, 150 610 
mM NaCl, 1% NP-40, 1% SDS, 1M PMSF, 1mM EDTA and proteinase 611 
inhibitors (cOmplete Mini, Roche). Lysates were cleared by centrifugation and 612 
incubated with anti-FLAG M2 agarose beads (Sigma-Aldrich), or with anti-613 
NAP1L1 Ab/IgG control and protein A/G agarose beads, washed several 614 
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times in RIPA and eluted in SDS-PAGE sample buffer. The following 615 
antibodies were used in this study: a sheep polyclonal against NS5A kindly 616 
provided by M. Harris (1:200 IF; 1:2000 WB) (81); a rabbit polyclonal against 617 
human NAP1L1 (Ab33076, Abcam) (1:200 IF; 1:1000 WB; 1:100 IP); a rabbit 618 
polyclonal against human IRF3 kindly provided by T. Fujita (1:100 IF); a rabbit 619 
monoclonal against human IRF3 (#4302 Cell Signaling) (1:500 WB); a rabbit 620 
monoclonal against phosphorylated human IRF3 (#4947 Cell Signaling) 621 
(1:500 WB); a rabbit monoclonal against human NF-κB p65/RELA (#8242 Cell 622 
Signaling) (1:100 IF; 1:1000 WB); a rabbit monoclonal against phosphorylated 623 
human NF-κB p65/RELA (#3033 Cell Signaling) (1:1000 WB); a mouse 624 
monoclonal against human β-actin conjugated with peroxidase (A3854 Sigma-625 
Aldrich) (1:10000 WB); a mouse monoclonal against the FLAG tag (F1804 626 
Sigma-Aldrich) (1:1000 WB); a mouse monoclonal against the HA tag 627 
conjugated with peroxidase (H6533 Sigma-Aldrich) (1:10000 WB). Secondary 628 
antibodies conjugated with AlexaFluor 488/594 were from Life Technologies 629 
(1:500 IF) and peroxidase conjugates from Dako (1:5000 WB).  630 
 631 
Luciferase assay and real-time quantitative reverse transcription PCR  632 
Luciferase assays were conducted essentially as described previously (79, 633 
80). For real-time quantitative reverse transcription PCR (qPCR) total cellular 634 
RNA was extracted with the isol-RNA reagent (5 Prime) and treated with 635 
DNAse I (Life Technologies). 500 ng were then reverse-transcribed with 636 
random primers and M-MLV Reverse Transcriptase (Life Technologies). 637 
Quantification of mRNA was obtained by real-time PCR using the Kapa Sybr 638 
fast qPCR kit on a CFX96 Bio-Rad thermocycler. Primers for amplification are 639 
available upon request. 640 
 641 
Transcriptome analysis by RNAseq 642 
Huh7-lunet cells were transduced with shNAP1L1 or shCTRL in triplicate and 643 
incubated with puromicin for 3 days. Total RNA (Isol RNA lysis, Reagent 5 644 
PRIME, Hamburg, DE) was extracted. Quality of extracted RNA was checked 645 
by gel electrophoresis (ribosomal 18S and 28S), spectrophotometric analysis 646 
(260/280>1.8) and Agilent bioanalyzer (RNA integrity number, RINt8). A 647 
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cDNA library of polyA-containing mRNA molecules was prepared (TruSeq, 648 
Illumina) and sequenced on the Illumina Platform (Hiseq2000 4-plex run, 50 649 
bp reads, about 30M reads/sample) at IGA Technology Services (Udine, 650 
Italy). Raw data were subjected to quality control (FastQC) and mapped 651 
against the human genome RNA reference from NCBI using CLCbio sotware. 652 
The Bioconductor packages DESeq2 version 1.4.5 (82) and EdgeR (83) 653 
version 3.6.2 in the framework of R software version 3.1.0 were used to 654 
perform the differential gene expression analysis of mRNAseq data. Both the 655 
packages are based on the negative binomial distribution (NB) to model the 656 
gene reads counts and shrinkage estimator to estimate the per-gene NB 657 
dispersion parameters. Specifically, we used rounded gene counts as input 658 
and we estimated the per-gene NB dispersion parameter using the function 659 
DESeq for DESEQ2 while, for edgeR we used the function calcNormFactors 660 
with the default parameters. To detect outlier data after normalization we used 661 
the R packages arrayQualityMetrix (84) and before testing differential gene 662 
expression we dropped all genes with normalized counts below 14 to improve 663 
testing power while maintaining type I error rates. Estimated p-values for each 664 
gene were adjusted using the Benjamini-Hochberg method (85). Genes with 665 
adjusted P<0.05 and absolute Logarithmic base 2 fold change  > 1 were 666 
selected. Data were finally analysed with the Ingenuity Pathway Analysis 667 
software. The significance values for the canonical pathway across the 668 
dataset shown in the Supplementary Table 1 are calculated by the Fisher’s 669 
exact test right-tailed. The significance indicates the probability of association 670 
of molecules from our dataset with the canonical pathway by random chance 671 
alone. 672 
 673 
Statistics 674 
Three independent experiments in triplicate repeats were conducted for each 675 
condition examined, unless otherwise indicated in the figure legends. Mean 676 
values are shown with standard deviation and p-values, measured with a 677 
paired two-tailed t-test. Only significant p-values are indicated by the asterisks 678 
above the graphs (p<0.01 = ** highly significant; p<0.05 = * significant). 679 
Where asterisks are missing the differences are calculated as non-significant. 680 
 681 
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Figure Legends 1014 
 1015 
Figure 1 – HCV NS5A binds NAP1L1. 1016 
A) Co-immune precipitation of flag-tagged NS5A and HA-NAP1L1 in HEK 1017 
293T cells. Transfected cells were lysed, co-IP with anti-FLAG agarose beads 1018 
and blotted against α-FLAG or α-HA antibodies as indicated. A plasmid 1019 
encoding for HIV-1 flag-tagged Tat was used as positive control. 1020 
B) NS5A interacts with endogenous NAP1L1 during HCV replication. Huh7-1021 
Lunet cells were electroporated with sub-genomic SGR-JFH1/Luc or mock 1022 
transfected. At 72 hpe cell lysates were incubated with α-NAP1L1 antibodies 1023 
or with matching irrelevant IgGs. Input and co-IP samples were then immuno-1024 
blotted with α-NAP1L1 and α-NS5A antibodies as indicated (IgH, 1025 
Immunoglobulin heavy-chain). 1026 
C) NS5A and NAP1L1 co-localize during HCV replication. Huh7-Lunet cells 1027 
were either mock electroporated or treated with the sub-genomic HCV 1028 
replicon SGR-JFH1/Luc or with SGR-FK-Luc-JFH1/ΔE1-E2 and fixed at 72 1029 
hpe. Indirect immunofluorescence analysis was performed with α-NAP1L1 1030 
(green) and α-NS5A (red) antibodies and corresponding fluorescent 1031 
secondary antibodies (scale bar 10 μm). Colocalization is shown in the merge 1032 
channel (Pearson’s correlation coefficient of 0.658 for SGR-JFH1/Luc and 1033 
0.731 for SGR-FK-Luc-JFH1/ΔE1-E2). The inset shows a high magnification 1034 
image. Diffused, cytoplasmic localization of NAP1L1 in mock cells is also 1035 
shown for comparison (above). 1036 
 1037 
Figure 2 – HCV JFH1 NS5A targets NAP1L1 for proteasome-mediated 1038 
degradation. 1039 
A) HCV NS5A from Con1 and H77 interact with NAP1L1. HEK293T cells were 1040 
transfected with flag-tagged NS5A from HCV genotypes as indicated. 1041 
Transfected cells were lysed, co-IP with α -FLAG agarose beads and blotted 1042 
against α-FLAG or α-HA antibodies. 1043 
B) HCV NS5A from JFH1 degrades NAP1L1. 293T cells were transfected with 1044 
equal amount of HA-NAP1L1 (5 μg) and increasing amount of flag tagged 1045 
NS5A from JFH1 or from Con1 (0, 2.5, 5 and 10 μg). After 24 hours cell 1046 
lysates were immunoblotted with α-FLAG, α-HA, and α-Actin antibodies. 1047 
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C) HCV NS5A-mediated degradation is proteasome dependent. HEK293T 1048 
cells were co-transfected with HA-NAP1L1 and flag-NS5A, treated with the 1049 
MG132 (5μM) for 14 h, and lysed. Samples were run and immunoblotted with 1050 
α-HA, α-FLAG and α-Actin antibodies. 1051 
D) HCV replication induces NAP1L1 degradation. Huh7-Lunet cells were 1052 
electroporated with SGR-JFH1/Luc RNA or mock transfected. Cells were 1053 
treated with 200 μM Cycloheximide (CHX) for 1 and 3 hours and lysed. 1054 
Samples were run and immunoblotted with α-HA, α-FLAG and α-Actin 1055 
antibodies. 1056 
E) CLUSTAL O (1.2.4) multiple sequence alignment NS5A from different HCV 1057 
genotypes. The asterisk character (*) indicates all the sequences that share 1058 
the same amino acid. Gaps are indicated by the minus character (-). The 1059 
cluster of Serines implcated in NS5A binding are boxed. 1060 
 1061 
Figure 3 – NAP1L1 interacts with the extreme carboxy-terminus of NS5A. 1062 
A) Diagram of NS5A and mutants produced in this work. The full-length of 1063 
JFH1 NS5A is shown with the flag-tag at the N-terminus, the amphipathic 1064 
helix (AH) for membrane tethering, domains I, II and III with the low-1065 
complexity sequences (LCS) I and II. AH-fused domain III (AH-D3-FL) is 1066 
deleted from the C-terminus in 6 fragments (AH-D3.1-6). The amino acid 1067 
sequence of the C-terminal region of NS5A encompassing S452/454/457A 1068 
(Serines are in bold) is also shown, together with the sequences of the 1069 
deletion mutant NS5A-delB and the triple S>A mutant NS5A-m2. 1070 
B) NAP1L1 binds Domain III of NS5A. HEK293T cells were transfected with 1071 
the indicated domains fused to AH together with HA-NAP1L1. Transfected 1072 
cells were lysed, co-IP with anti-FLAG agarose beads and blotted against α-1073 
FLAG or α-HA antibodies. White asterisks (*) indicate the position of the 1074 
NS5A mutants that are distinguishable from the heavy (IgH) and light (IgL) 1075 
immunoglobulin chains. 1076 
C) NAP1L1 binds the extreme C-terminus of NS5A. HEK293T cells were 1077 
transfected with expression plasmids encoding for NS5A Domain III fused to 1078 
AH carrying progressive deletions from the C-terminus as indicated in the 1079 
diagram (Figure 3A). Co-IP was conducted as in Figure 3B. 1080 
D) NS5A mutants delB and m2 do not bind NAP1L1. HEK293T were 1081 
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transfected with expression plasmids for NS5A mutants delB and m2 1082 
described in Figure 3A. Co-IP was conducted as in Figure 3B. 1083 
E) NS5A mutants delB and m2 lose colocalization with NS5A. Huh7-Lunet 1084 
cells were electroporated with SGR-JFH1/Luc and with mutants SGR-1085 
JFH1/Luc_m2 and SGR-JFH1/Luc_delB and fixed at 72 hpe. Indirect 1086 
immunofluorescence analysis was performed with α-NAP1L1 (green) and α-1087 
NS5A (red) antibodies and corresponding fluorescent secondary antibodies 1088 
(scale bar 10 μm). Colocalization is shown in the merge channel. 1089 
 1090 
Figure 4 – HCV does not require NAP1L1 for replication and infectivity 1091 
A) NS5A and NAP1L1-EYFP co-localize during HCV replication. Huh7-Lunet 1092 
cells were transduced with a lentiviral vector (LV) expressing NAP1L1-EYFP 1093 
and then either mock electroporated or treated with the sub-genomic HCV 1094 
replicon SGR-JFH1/Luc and fixed at 72 hpe. Indirect immunofluorescence 1095 
analysis was performed with α-NS5A (red) (scale bar 10 μm). 1096 
B) NAP1L1 overexpression does not affect HCV genome replication. Huh7-1097 
Lunet cells were transduced with a lentiviral vector (LV) expressing EYFP or 1098 
NAP1L1-EYFP at an efficiency >85% on average as measured by 1099 
cytofluorimetric analysis. Cells were then electroporated with the HCV SGR 1100 
JFH1/Luc RNA and luciferase monitored at the indicated time points. Values 1101 
are normalized to the luciferase signal at 4 hours post-electroporation. 1102 
Average of 3 independent replicates are shown with standard deviations. 1103 
C) Depletion of NAP1L1 by shRNA. Huh7-Lunet cells were transduced with 1104 
LV expressing shRNA targeting NAP1L1 (shNAP1L1) or non-targeting control 1105 
(shCTRL). After selection with puromycin, cells were electroporated with HCV 1106 
SGR JFH1/Luc RNA and protein levels detected by WB. 1107 
D) Depletion of NAP1L1 does not affect HCV genome replication. Huh7-Lunet 1108 
cells were treated as in Figure 4C and the luciferase signal measured as in 1109 
Figure 4B.  1110 
E) Depletion of NAP1L1 does not affect HCV infectivity. Huh7-Lunet cells 1111 
treated with shRNAs as in Figure 4C were electroporated with full-length HCV 1112 
JFH1 RNA. At the indicated time points, the supernatant was collected and 1113 
used to infect naïve Huh7.5 cells at various dilutions. The 50% tissue culture 1114 
infectious dose (TCID50) was then calculated counting cells stained with the 1115 
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NS5A antiserum. 1116 
F) Mutagenesis of the NAP1L1 binding site of NS5A does not affect HCV 1117 
genome replication. Huh7-Lunet cells were electroporated with HCV SGR 1118 
JFH1/Luc RNA from wt, the m2 mutant of NS5A or the GND mutant of NS5B, 1119 
which is replication defective. Luciferase was measured as in Figure 4B. 1120 
 1121 
Figure 5 – The interaction with HCV NS5A inhibits NAP1L1 nuclear 1122 
translocation. 1123 
A) SGR-JFH1 NS5A inhibits NAP1L1 nuclear localization. Huh7-Lunet cells 1124 
were electroporated with HCV SGR-JFH1/Luc RNA or the mutant replicon 1125 
SGR-JFH1/m2 or control SGR-JFH1/GND as indicated. At 63 h.p.e., cells 1126 
were treated with 150 nM LMB for 9 hours. Cells were then fixed and stained 1127 
for NS5A and NAP1L1. Scale bar = 10 μm. 1128 
B) Quantification of SGR-JFH1 NS5A inhibition of NAP1L1 nuclear 1129 
localization. 300 cells treated as in Figure 5A were visually scored for NAP1L1 1130 
nuclear localization in the presence of NS5A. The investigator was blinded to 1131 
the group allocation during visual counting. Average of 3 independent 1132 
replicates are shown with standard deviations. 1133 
C) Con1 NS5A mutant m2 does not bind NAP1L1. HEK293T were transfected 1134 
with expression plasmids for Con1 NS5A and m2. Co-IP was conducted as in 1135 
Figure 3B. 1136 
D) Both JFH1 and Con1-derived NS5A inhibit nuclear translocation of 1137 
NAP1L1. Huh7-Lunet cells were transfected with expression plasmids for 1138 
NS5A from JFH1 or Con1 and their respective m2 mutants. Cells were treated 1139 
with LMB as described above, fixed and stained for ectopic flag-tagged NS5A 1140 
and endogenous NAP1L1. Scale bar = 10 μm. 1141 
E) Quantification of NS5A inhibition of NAP1L1 nuclear localization. Cells 1142 
treated as in Figure 5C were visually scored as described above (Figure 5B). 1143 
 1144 
Figure 6 – NAP1L1 is involved in the innate immunity response. 1145 
A) Whole-genome transcriptome analysis in NAP1L1-depleted cells. Huh7-1146 
Lunet cells were treated with shNAP1L1/shCTRL followed by RNAseq 1147 
analysis. Black bars show the levels of 15 down-regulated genes (fold change 1148 
≤ -2) and 2 up-regulated genes (fold change ≥ 2), which were further validated 1149 
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by qRT-PCR (grey bars) normalized for β-actin.  1150 
B) Induction of ISG genes is not NAP1L1-dependent. Huh7-Lunet cells were 1151 
treated with 1000 U/ml of IFNα for 8 hours. UBD, GBP2, IFITM3 and GAPDH 1152 
mRNA was measured by qRT-PCR normalized for β-actin in triplicate 1153 
independent experiments. Shown are fold changes over basal, non induced 1154 
levels ± SD. 1155 
C) IFN induction following poly(I:C) transfection in different cell lines. U2OS, 1156 
Huh7-lunet and Huh7.5 were were transfected with 1 μg poly(I:C) for 8 hours. 1157 
IFNβ mRNA levels were measured by qRT-PCR, normalized for β-actin and 1158 
plotted against mock (lipofectamine). Average of 3 independent replicates are 1159 
shown with standard deviations. 1160 
D) NAP1L1 depletion affects the induction of IFNβ mRNA by poly(I:C). U2OS 1161 
cells treated with shNAP1L1/shCTRL for 3 days were transfected with 1 μg 1162 
poly(I:C) for 8 hours. IFNβ mRNA levels were measured as above. 1163 
E) NAP1L1 depletion affects the induction of IFNβ by poly(I:C). U2OS cells 1164 
were treated as above (Figure 6C). Secreted IFNβ protein was measured by a 1165 
commercial ELISA in triplicate, quantified against a standard curve and 1166 
plotted. 1167 
 1168 
Figure 7 – NAP1L1 controls RELA levels and IRF3 activation. 1169 
A) NAP1L1 depletion affects RELA levels and IRF3 phosphorylation. U2OS 1170 
cells were transduced with LV for shNAP1L1 or shCTRL and subsequently 1171 
transfected with 1 μg poly(I:C) using lipofectamine (lipo). Protein levels as 1172 
indicated were monitored by WB at 1-2-4 hours post transfection of poly(I:C).  1173 
B) NAP1L1 depletion decreases RELA protein levels. Blots as in Figure 7A 1174 
were quantified to measure RELA and IRF3 protein levels using ImageJ. 1175 
Shown is the ratio shNAP1L1/shCTRL in cells not transfected with poly(I:C). 1176 
Average of 3 independent replicates are shown with standard deviations.  1177 
C) NAP1L1 depletion affects IRF3 phosphorylation. Blots as in Figure 7A 1178 
were quantified to measure RELA and IRF3 phosphorylation levels using 1179 
ImageJ. Shown is the ration phosphorylated/total protein in cells transfected 1180 
with poly(I:C). Average of 3 independent replicates are shown with standard 1181 
deviations. 1182 
D) NAP1L1 depletion reduces RELA nuclear translocation. U2OS cells were 1183 
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transduced with LV for shNAP1L1 or shCTRL and subsequently transfected 1184 
with 1 μg poly(I:C) for 8 hours. Cells were then fixed and stained for RELA. 1185 
E) NAP1L1 depletion reduces RELA nuclear translocation. Around 500 cells 1186 
from the experiment shown in Figure 7D were counted for each condition to 1187 
calculate the percentage of RELA nuclear translocation. Average of 3 1188 
independent replicates are shown with standard deviations.  1189 
F) NAP1L1 depletion reduces IRF3 nuclear translocation. U2OS cells were 1190 
transduced with LV for shNAP1L1 or shCTRL and subsequently transfected 1191 
with 1 μg poly(I:C) for 8 hours. Cells were then fixed and stained for IRF3. 1192 
G) NAP1L1 depletion reduces IRF3 nuclear translocation. Around 500 cells 1193 
from the experiment shown in Figure 7F were counted for each condition to 1194 
calculate the percentage of IRF3 nuclear translocation. Average of 3 1195 
independent replicates are shown with standard deviations.  1196 
H) HCV NS5A inhibits TBK1-mediated activation of IFNβ. HEK 293T cells 1197 
were transfected with expression vectors for FLAG-tagged TBK1, NS5A or the 1198 
mutants NS5A-m2 together with a reporter plasmid carrying the firefly 1199 
luciferase (Fluc) gene under the control of the IFNβ promoter (pIFNβ-Luc) and 1200 
the control pCMV-Renilla. Relative light units (RLUs) of luciferase activity was 1201 
measured in quintuplicate independent experiments, normalized for Renilla, 1202 
and represented as fold change over mock ± SD.  1203 
 1204 
Figure 8 – NAP1L1 controls IRF3 phosphorylation at the TBK1/IKKε 1205 
level. 1206 
A) Schematic representation of the RIG-I and TLR3 pathways. Both lead to 1207 
activation of NF-κB and phosphorylation of IRF3 through MAVS/TBK1/IKKe or 1208 
TRIF, respectively. NF-κB and pIRF3 translocate to the nucleus and activate 1209 
IFNβ and other ISGs.  1210 
B) NAP1L1 does not affect constitutive IRF3-5D activity. Huh7-Lunet cells 1211 
were transduced with LV for shNAP1L1 or shCTRL and subsequently 1212 
transfected with an expression vector for IRF3-5D, the reporter IFNβ-Luc and 1213 
the Renilla control. Cell lysates were blotted as indicated. 1214 
C) NAP1L1 does not affect constitutive IRF3-5D activity. Luciferase activity of 1215 
cells from the experiment shown in Figure 7H was measured in triplicate 1216 
independent experiments, normalized for Renilla. Average values are shown 1217 
 39 
with standard deviations.  1218 
D) Depletion of NAP1L1 affects TBK1/IKKε-mediated activation of IFNβ. HEK 1219 
293T cells were transduced with LV for shNAP1L1 or shCTRL and 1220 
subsequently transfected with expression vectors for FLAG-tagged RIG-I, 1221 
IPS-1/MAVS, TBK1 and IKKε together with the reporter IFNβ-Luc and the 1222 
Renilla control. Cell lysates were blotted with anti-FLAG as indicated. 1223 
Luciferase activity was measured in triplicate independent experiments, 1224 
normalized for Renilla, and represented as fold change over mock ± SD.  1225 
 1226 
Figure 9 – NAP1L1 controls the TLR3 pathway. 1227 
A) Depletion of NAP1L1 affects TRIF-mediated activation of IFNβ. Huh7-1228 
Lunet cells were transduced with LV for shNAP1L1 or shCTRL and 1229 
subsequently transfected with expression vectors for TRIF together with the 1230 
reporter IFNβ-Luc and the Renilla control. Luciferase activity was measured in 1231 
triplicate independent experiments, normalized for Renilla, and represented 1232 
as fold change over mock ± SD. 1233 
B) Depletion of NAP1L1 by LV shRNA treatment. Huh7-Lunet cells were 1234 
transduced with LV for shNAP1L1 or shCTRL and then with LV expressing 1235 
TLR3 or EGFP as control. 50 μg of Poly(I:C) was added to the medium for 24 1236 
hours. IFNβ mRNA levels for NAP1L1 were measured by qRT-PCR, 1237 
normalized for β-actin and plotted against mock. Average of 3 independent 1238 
replicates are shown with standard deviations. 1239 
C) Reconstitution of the TLR3 pathway. Cells were processed and TLR3 1240 
mRNA quantified as in Figure 9B above.  1241 
D) Depletion of NAP1L1 affects TLR3 signaling. Cells were processed and 1242 
IFIT1 mRNA quantified as in Figure 9B above.  1243 
 1244 
 1245 
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